{"id":"W3011495178","doi":"10.1002/cncr.32811","title":"NRG/RTOG 1122: A phase 2, double‐blinded, placebo‐controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma","year":2020,"lang":"en","type":"article","venue":"Cancer","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital","funders":"National Cancer Institute; Amgen","keywords":"Bevacizumab; Medicine; Clinical endpoint; Placebo; Gliosarcoma; Progression-free survival; Internal medicine; Phases of clinical research; Surgery; Adverse effect; Glioblastoma; Oncology; Randomized controlled trial; Clinical trial; Overall survival; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002789665,0.002388029,0.003169999,0.0006433894,0.0004366194,0.001122105,0.001187844,0.002032713,0.006302414],"category_scores_gemma":[0.001939364,0.001027713,0.001562759,0.0005274485,0.001433102,0.001290224,0.0003748417,0.002829036,0.00130575],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008807203,"about_ca_system_score_gemma":0.001626737,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001086317,"about_ca_topic_score_gemma":0.002631098,"domain_scores_codex":[0.9989461,0.0005720062,0.00006515806,0.000203568,0.00008790666,0.0001253396],"domain_scores_gemma":[0.99935,0.0001329238,0.0001627653,0.00006551533,0.00005699486,0.0002318927],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9448246,0.01950232,0.0007013124,0.000845366,0.0007837221,0.00005361109,0.00008229815,0.0003556574,0.008979334,0.00009766122,0.001134215,0.02264003],"study_design_scores_gemma":[0.9310501,0.06693231,0.0008585774,0.000015255,0.0001801278,0.00002857645,0.000009305825,0.000211053,0.0003105291,0.00003864407,0.0003543012,0.00001116881],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851109,0.003992151,0.0008159673,0.0007216512,0.0004514178,0.005536161,0.001240961,0.0002801947,0.001850601],"genre_scores_gemma":[0.9815521,0.002570425,0.002159177,0.001347887,0.0004485097,0.007369103,0.001458261,0.00004689602,0.003047592],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006302414,"threshold_uncertainty_score":0.02108371,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02214749316887849,"score_gpt":0.3016023983414542,"score_spread":0.2794549051725758,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}